Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis

Abstract

Background The discovery of signaling networks that drive oncogenic processes has led to the development of targeted anticancer agents. The burden of pigmentary adverse events from these drugs is unknown. Objective To conduct a systematic review and meta-analysis of published clinical trials, and determine the incidence and risk of developing targeted therapy-induced pigmentary changes. Methods A comprehensive search was conducted to identify studies reporting targeted therapy-induced pigmentary changes. The incidence and relative risk were calculated. Case reports and series were reviewed to understand clinical characteristics. Results 8,052 patients from 36 clinical trials were included. The calculated overall incidences of targeted cancer therapy-induced all-grade pigmentary changes in the skin and hair were 17.7% (95% CI, 11.9–25.4) and 21.5% (95% CI, 14.9–30.1), respectively. The relative risk of all-grade pigmentary changes of skin and hair were 93.7 (95% CI: 5.86–1497.164) and 20.1 (95% CI: 8.35–48.248). Across 54 case reports/series (n=75 patients), EGFR and Bcr-abl inhibitors were the most common offending agents. Limitations Potential underreporting and variability in oncologists reporting these events. Conclusion There is a significant risk of developing pigmentary changes during treatment with targeted anticancer therapies. Appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life.

Eyelashes depigmentation following treatment with pazopanib for metastatic renal cell carcinoma

“…In a few reported cases, hypopigmentation usually appeared after 1 to 3 cycles of therapy and it gradually developed after maximum 6 to 10 cycles (Sideras et al, ). Our case, however, required more time, being anyway in line with a systematic review and meta‐analysis of published clinical trials that reported the time of onset of pigmentary changes in patients treated with targeted anticancer agents, from “immediately” to up to 10 years after initiation of treatment (Dai et al, ; Sideras et al, ). A case of rapid overnight hair and eyebrow depigmentation in a patient affected by renal cell carcinoma during the second cycle of pazopanib was described.…”

Osimertinib-associated ashy dermatosis–like hyperpigmentation

“…However, pigmentary changes in association with EGFR-TKI treatment are rarely reported. 2 Here, we describe an unusual case of slate gray hyperpigmentation associated with osimertinib therapy.…”

An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics

“…In particular, with molecular-targeted drugs widely used, adverse effects of such treatments including acneiform eruptions, paronychia, xerosis, mucositis, and alopecia are thought to be less severe, but can still be significant (6). Not only can these toxicities severely affect patients' QOL, but in some specific instances, they can be associated with increased response to therapy (7). Therefore, it is of paramount importance that clinicians familiarize themselves with the basic management of the adverse effects caused by these drugs.…”